Log in Free sign up

Ideaya Biosciences (IDYA) News and press releases

News

From Benzinga Pro

Recap: IDEAYA Biosciences Q1 Earnings

IDEAYA Biosciences (NASDAQ:IDYA) reported its Q1 earnings results on Tuesday, May 10, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

IDEAYA Biosciences Q1 EPS $(0.36) Down From $(0.28) YoY

IDEAYA Biosciences (NASDAQ:IDYA) reported quarterly losses of $(0.36) per share. This is a 28.57 percent decrease over losses of $(0.28) per share from the same period last year.

FDA Grants Orphan Drug Designation For IDEAYA's Darovasertib For Uveal Melanoma

Biotech, News, Health Care, Small Cap, FDA, General

The U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to IDEAYA Biosciences (NASDAQ: IDYA) for its drug candidate Darovasertib for the treatment of uveal melanoma.

IDEAYA Biosciences Receives Orphan Drug Designation For Darovasertib, A PKC Inhibitor, For The Treatment of Uveal Melanoma

Biotech, News, FDA, General

- Darovasertib designated as an Orphan Drug by the U.S. FDA, entitling IDEAYA to certain tax credits, exemption from user fees, and potential statutory marketing exclusivity - Targeting a clinical data

Stocks That Hit 52-Week Lows On Thursday

News, Options, Intraday Update, Markets

During Thursday, 849 stocks hit new 52-week lows.

IDEAYA Biosciences Granted FDA Orphan Drug Designation Wednesday for Darovasertib for Treatment of Uveal Melanoma

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=873322

Stocks That Hit 52-Week Lows On Monday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Monday, 466 companies hit new 52-week lows.

Stocks That Hit 52-Week Lows On Wednesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Wednesday, 90 companies set new 52-week lows.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Pre-Market Outlook, Markets, Movers

Ideaya Biosciences' IDE397 Shows Preliminary Tolerability In Early-Stage Solid Tumor Trial

Biotech, News, Health Care, Small Cap, General

IDEAYA Biosciences Inc (NASDAQ: IDYA) has announced

The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial

Biotech, Earnings, News, Penny Stocks, Offerings, Small Cap, FDA, General

Here's a roundup of top developments in the biotech space over the last 24 hours:

IDEAYA Biosciences Q4 EPS $(0.47) Misses $(0.31) Estimate, Sales $2.96M Miss $8.98M Estimate

IDEAYA Biosciences (NASDAQ:IDYA) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.31) by 51.61 percent. This is a 161.11 percent decrease over losses of $(0.18) per share

Recap: IDEAYA Biosciences Q4 Earnings

IDEAYA Biosciences (NASDAQ:IDYA) reported its Q4 earnings results on Tuesday, March 15, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Earnings Scheduled For March 15, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • IDEAYA Biosciences (NASDAQ:IDYA) is likely to report quarterly loss at $0.31 per share on revenue of $8.98 million.

IDEAYA Biosciences's Earnings: A Preview

IDEAYA Biosciences (NASDAQ:IDYA) is set to give its latest quarterly earnings report on Tuesday, 2022-03-15. Here's what investors need to know before the announcement. Analysts estimate that IDEAYA Biosciences will report an earnings per share (EPS) of $-0.31.

IDEAYA And Pfizer Expand Clinical Trial Collaboration and Supply Agreements For Evaluation Of Darovasertib And Crizotinib Combination In Metastatic Uveal Melanoma And Additional cMET-Driven Tumors

Biotech, General

IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that it has entered into additional

The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings

Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, Top Stories, General

Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments served as catalysts during the week.

Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2022

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Stifel Upgrades IDEAYA Biosciences to Buy, Lowers Price Target to $20

News, Upgrades, Price Target, Analyst Ratings

Stifel analyst Benjamin Burnett upgrades IDEAYA Biosciences (NASDAQ:IDYA) from Hold to Buy and lowers the price target from $27 to $20.

Stocks That Hit 52-Week Lows On Tuesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

Tuesday's session saw 729 companies set new 52-week lows.

Press releases

From Benzinga Pro

IDEAYA Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

Earnings, Press Releases

Strong balance sheet of ~$346 million cash, cash equivalents and marketable securities as of March 31, 2022 is anticipated to fund planned operations into 2025Targeting initiation of IDE397 Phase 1/2 monotherapy

IDEAYA Biosciences to Participate in Investor Conferences in May 2022

SAN FRANCISCO, May 3, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics,

IDEAYA Biosciences Receives Orphan Drug Designation for Darovasertib, a PKC Inhibitor, for the Treatment of Uveal Melanoma

- Darovasertib designated as an Orphan Drug by the U.S. FDA, entitling IDEAYA to certain tax credits, exemption from user fees, and potential statutory marketing exclusivity - Targeting a clinical data update for

IDEAYA Biosciences Appoints Catherine Mackey, Ph.D., to its Board of Directors

- Dr. Mackey formerly served as Senior Vice President of Pfizer Worldwide Research and Development and as Director of Pfizer's La Jolla Laboratories SOUTH SAN FRANCISCO, Calif., April 6, 2022 /PRNewswire/ -- IDEAYA

IDEAYA Biosciences, Inc. Reports 2021 Financial Results and Provides Business Update

Earnings, Press Releases

- Strong balance sheet of ~$368 million cash, cash equivalents and marketable securities as of December 31, 2021 is anticipated to fund planned operations into 2025 - Enrolling into IDE397 Cohort 6 with no observed

IDEAYA Biosciences Reports IDE397 Interim Phase 1 Clinical Data

Observed preclinical complete suppression (~95-100%) of tumor SDMA in multiple MTAP-deleted patient derived xenograft (PDX) models across indications Interim IDE397 clinical data demonstrates robust plasma

IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreements for Evaluation of Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma and Additional cMET-Driven Tumors

News, Contracts, Press Releases

SOUTH SAN FRANCISCO, Calif., March 14, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of

IDEAYA Biosciences Announces Investor Webcast to Report Interim IDE397 Phase 1 Clinical Data and Corporate Update

SOUTH SAN FRANCISCO, Calif., March 8, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted

IDEAYA Biosciences to Participate in Investor Conferences in March 2022

SOUTH SAN FRANCISCO, Calif., March 1, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted